[{"orgOrder":0,"company":"Unlimited Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Unlimited Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unlimited Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Unlimited Sciences \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Unlimited Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : Ayahuasca produces powerful experiences that have been likened to intense psychotherapy, indicating its therapeutic potential for treating trauma and its resulting mental health disorders, such as post-traumatic stress disorder (PTSD).

                          Product Name : Ayahuasca

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 02, 2022

                          Lead Product(s) : Dimethyltryptamine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank